Our live Investing Matters Podcast Special which took place at the Master Investor Show discussing 'How undervalued is the UK stock market?', has just been released. Listen here.
To achieve capital growth through investing in high growth, development stage biotechnology companies.
Find out MoreLondon South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
We don't know people's circumstances and the directors aren't likely to pop in here and hear your request. Look on the bright side at least some of the directors do buy, I've other ITs where no directors ever buy and that is demoralising.
please buy more shares in the company to demonstrate your belief and be more aligned with us shareholders. especially patrick maxwell and gillian el****.
Very heavy volume, in the equity, which began 1/8/23. A bullish double bottom is in place. The negative is overhead supply, from previous higher bottoms, which can impede upward movement. Perhaps wait until sp, confirms support, above
640 by retracement, before buying. That price level could also be used as a stop , after satisfactory evidence, or at least temporary base building.
That's a wonderfully Brit way of putting it. At best there's going to be a headwind for the next year and it sounds more like a disaster to me.
Rather odd this, Bingham handles the unquoted portfolio and as the vaccine expert is well connected, anyone have any thoughts ?
We don't seem to be getting daily NAV RNSs any more. However, it's still being given on their home page
https://ibtplc.com/
and the HL chart (30 Mar post) is still being updated.
I just bought some on a 10% discount, I like the trust, & the sector, so 10% dis made a compelling reason for me to top up.
The trust have been buying back the shares as well so how much wider is the dis likely to go to ?
Discount to NAV is getting quite wide now. Any theories?
https://www.hl.co.uk/shares/shares-search-results/i/international-biotechnology-trst-ord-25p/share-charts
Agreed !
Cheap trust with a yield, a discount & potential.
Hugely undervalued IMO. I will sit tight and wait for this to realise some of its potential.
... for me but up today against the market, so maybe a few more think like me.
Very helpful and I have today invested here, after further research of my own. Did look at BBBiotech but thought it too concentrated. This looks in a temporary dip and, all other things being =, should resume better path in 2022, or possibly in anticipation. Decent dividend as well. Only 2.5% of portfolio. Definitely safer than AIM rubbish.
The company posted a positive return in the year, though opportunities were curtailed by an agreement with the UK Government to avoid investment in vaccine producers while Kate Bingham worked as Chair of the Vaccine Taskforce (this restriction is due to be lifted at the end of December 2021). Excluding these stocks from the benchmark index would have seen the portfolio outperform. The team retain a favourable outlook, citing a strong pace of innovation and demographic drivers to growth alongside a relatively stable benign regulatory environment. As face-to-face meetings resume and valuations of smaller companies in the sector have corrected to lower levels, the team anticipate a resurgence in mergers and acquisitions, with larger companies having strong balance sheets and needing to replenish development pipelines.
IBT shares closed yesterday on a c. 5% discount to net asset value and a 3.9% historic dividend yield. Ongoing charges were 1.2% in the year excluding performance fees or 1.3% including this charge; the Key Information Document impact on return figure equates to 1.67%.
Highlights from the report:
The company has posted a net asset value (NAV) total return of 9.8%, lagging the 22.8% return from the NASDAQ Biotechnology Index. The share price return was 3.8% as the discount to NAV widened.
Underperformance is attributed to a lack of exposure to vaccine producing companies under an agreement between the manager and the UK Government when lead portfolio manager Kate Bingham was working as the Chair of the Vaccine Taskforce. This restriction is due to be lifted at the end of December 2021.
Moderna, one of two companies to develop an mRNA vaccine for COVID-19, became the largest biotech company in the world as its share price rose by c. 500%, contributing 12.3% of the 22.8% index return. If vaccine contributions were altogether excluded from benchmark returns, the index would have posted an 8.2% gain, below that posted by the fund.
The quoted portfolio, accounting for 91% of NAV, returned 11.2% in the year whilst the unquoted portfolio returned 23.9%, driven by holdings in the SV Fund VI.
Immunomedics was the largest single contributor to NAV following its acquisition by Gilead after positive data and FDA approval of its lead asset, Trodelvy, a therapy for the treatment of advanced breast cancer. Other material contributors included Biohaven Pharmaceutical, and Horizon Therapeutics.
Only just saw date of original post
Try
https://ibt.ams3.digitaloceanspaces.com/files/April-factsheet-final.pdf
Don't know if you can access directly or HAVE to go off the the Investor Relations link on the site
atb
Link doesn't work
IBT announced via an RNS on 21 Apr that they've updated their portfolio. Does anyone know what companies they added/dropped from the fund portfolio? I've followed the link in the RNS but it is not obvious.
Underporming other funds and the index even taking into consideration the dividend. Why the poor NAV?
"During June, the Income portfolio added to its existing holdings in Scottish Mortgage Trust (SMT) and International Biotechnology Trust (IBT). "
https://www.investorschronicle.co.uk/tips-ideas/2018/07/06/biotechnology-best-yet-to-come/
You can meet the managers of International Biotechnology Trust at the Mello Trust and Funds Show. We all have discounted tickets available from ShareSoc, full members get an originally £49 ticket for the reduced price of £24.50 - hTTps://www.sharesoc.org/blog/education/learn-from-experts-at-the-mello-investment-trust-and-funds-conference/
Sheepy, surely the whole point of investing in an Investment Trust is to spread your risk and put the investment decision in the hands of experts, rather than picking up a dart, putting on a blindfold and hoping to hit the bullseye with a ten-bagger.
GILD proves the point, essentially going sideways over 14 months, oscillating between $64 and $85, currently $70. Unless you're a very short-term trader, with low dealing and currency costs, there hasn't been much opportunity.
Whereas, during the same 14 months IBT has done exactly the same thing - today at 597p, after a 700p high in August. Biotech is a long-term horizon investment, imho, five years minimum.
Looks like the share price went up and now record highs! I am still in, botech sector as I still see value but totally understand than US stocks could be due a fall and this 85% North America. There are UK and European biopharmaceutical funds if the fundmangers to not switch.